BJDX — Bluejay Diagnostics Inc
NASDAQ · Healthcare · Medical Devices
$0.85
-$0.02 (-2.59%)
Bluejay Diagnostics Inc (BJDX) is a medical devices company listed on NASDAQ. It is led by Indranil Dey, based in 360 Massachusetts Avenue, Acton, MA, United States, 01720, with about 6 employees. Bluejay Diagnostics, Inc. operates as a medical diagnostics company. It offers Symphony technology platform which consists of an analyzer and single-use protein detection cartridges that are designed to provide measurements of key diagnostic biomarkers found in blood; and Symphony analyzer used to orchestrate sample processing of whole blood, plasma, serum, etc., biomarker isolation, and immunoassay preparation using non-contact centrifugal force. The company also develops Symphony IL-6 tests for the monitoring of disease progression in critical care settings. In addition, it develops additional tests for Symphony, such as tests for myocardial infraction and congestive heart failure, as well as other tests using the Symphony platform. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Net income was -$1.6M. BJDX currently screens at market cap $5.0M.
Use this BJDX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the BJDX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the BJDX SEC filings page. Lician reads the product cache first so this HTML stays unique to Bluejay Diagnostics Inc even when a live quote feed is slow.
About Bluejay Diagnostics Inc
Bluejay Diagnostics, Inc. operates as a medical diagnostics company. It offers Symphony technology platform which consists of an analyzer and single-use protein detection cartridges that are designed to provide measurements of key diagnostic biomarkers found in blood; and Symphony analyzer used to orchestrate sample processing of whole blood, plasma, serum, etc., biomarker isolation, and immunoassay preparation using non-contact centrifugal force. The company also develops Symphony IL-6 tests for the monitoring of disease progression in critical care settings. In addition, it develops additional tests for Symphony, such as tests for myocardial infraction and congestive heart failure, as well as other tests using the Symphony platform. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
BJDX Key Statistics
Market Cap
$4.97M
Volume
82,294
Previous Close
$0.90
Day Range
$0.90 – $0.96
EPS
-$114.19
Revenue
$0.00
Net Income
-$7.72M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
6
BJDX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $249.04K | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$7.72M | -$9.95M | -$9.30M | -$3.49M |
| EPS (Diluted) | -$114.19 | -$3.63K | -$9.22 | -$0.41 |
Total Assets
$6.66M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$4.30M
Operating Cash Flow
-$7.82M
Free Cash Flow
$0.00
Bluejay Diagnostics Inc Company Information
- Principal Financial, Accounting & Executive Officer, President, CEO and Director
- Indranil Dey
- Headquarters
- 360 Massachusetts Avenue, Acton, MA, United States, 01720
- Website
- bluejaydx.com
- Phone
- 844 327 7078
- IPO / Founded
- 2021-11-10
- Sector
- Healthcare
- Industry
- Medical Devices